BTIG analyst Julian Harrison raised the firm’s price target on Ardelyx (ARDX) to $17 from $14 and keeps a Buy rating on the shares. Ardelyx pre-announced strong FY25 results and issued 2026 Ibsrela guidance of $410-$430M, supporting confidence in a path to more than $1B peak sales, aided by a large, underpenetrated IBS-C market, a new Phase 3 CIC trial, and extended IP potential to 2041, the analyst tells investors in a research note. Alongside growing Xphozah revenue, a progressing pipeline, and a strong cash position, Ardelyx is well-positioned to sustain commercial growth and fund future development, the firm says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx: Strengthening Commercial Trajectory, Expanded IP Protection to 2041, and Pipeline Upside Support Raised $17 Buy Target
- Ardelyx upgraded to Overweight from Neutral at Piper Sandler
- Ardelyx price target raised to $19 from $16 at Raymond James
- Ardelyx files procedural regulatory disclosure update notice
- Ardelyx sees FY26 revenue IBSRELA between $410M-$430M